Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zelenectide Pevedotin in Previously-Treated NECTIN4 Amplified Advanced or Metastatic NSCLC
NCT06933329Phase 2Active, not recruiting
- Sponsor
- Bicycle Therapeutics
- Start
- Jul 2025
- Primary completion
- Aug 2028
- Modality
- Cyclic Peptides, Antibody-Drug Conjugates (ADCs), Peptide-Drug Conjugates
- Countries
- 2
01
Overview
Phase 2, open-label trial of zelenectide pevedotin in non-small cell lung cancer (NSCLC) (2 cohorts), sponsored by Bicycle Therapeutics. Primary endpoint: Objective Response Rate at 3 years. Started Jul 2025; status: active, not recruiting.
02
Drugs
zelenectide pevedotin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06933329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06933329.